Refine
Document Type
- Article (2)
Language
- English (2)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Euphorbia section Anisophyllum (1)
- Euphorbia section Crossadenia (1)
- Neotropics (1)
- T cells (1)
- antibodies (1)
- caatinga (1)
- cancer (1)
- cerrado (1)
- cytomegalovirus (1)
- immune responses (1)
Institute
- Medizin (1)
We describe and illustrate three new species of Euphorbia subgenus Chamaesyce from Brazil: E. blepharadena O.L.M.Silva & Cordeiro sp. nov., E. longipedunculata O.L.M.Silva & Riina sp. nov. and E. sobolifera O.L.M.Silva & P.J.Braun sp. nov. Based on morphological characteristics, E. blepharadena sp. nov. and E. longipedunculata sp. nov. are placed in the subcosmopolitan section Anisophyllum, whereas E. sobolifera sp. nov. is placed in the more geographically restricted section Crossadenia. The three new species are compared with their most similar species in each section, and accompanied by comments on habitat and distribution, illustrations, photographs, and proposed conservation status.
Clinically relevant immune responses against Cytomegalovirus : implications for precision medicine
(2019)
Immune responses to human cytomegalovirus (CMV) can be used to assess immune fitness in an individual. Further to its clinical significance in posttransplantation settings, emerging clinical and translational studies provide examples of immune correlates of protection pertaining to anti-CMV immune responses in the context of cancer or infectious diseases, e.g., tuberculosis. In this viewpoint, we provide a brief overview about CMV-directed immune reactivity and immune fitness in a clinical context and incorporate some of our own findings obtained from peripheral blood or tumour-infiltrating lymphocytes (TIL) from patients with advanced cancer. Observations in patients with solid cancers whose lesions contain both CMV and tumour antigen-specific T-cell subsets are highlighted, due to a possible CMV-associated "bystander" effect in amplifying local inflammation and subsequent tumour rejection. The role of tumour-associated antibodies recognising diverse CMV-derived epitopes is also discussed in light of anti-cancer immune responses. We discuss here the use of anti-CMV immune responses as a theranostic tool—combining immunodiagnostics with a personalised therapeutic potential—to improve treatment outcomes in oncological indications.